Ligand Pharmaceuticals (LGNYZ) Accumulated Depreciation & Amortization (2016 - 2024)
Historic Accumulated Depreciation & Amortization for Ligand Pharmaceuticals (LGNYZ) over the last 13 years, with Q4 2024 value amounting to $35.2 million.
- Ligand Pharmaceuticals' Accumulated Depreciation & Amortization fell 351.03% to $35.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $35.2 million, marking a year-over-year decrease of 351.03%. This contributed to the annual value of $35.2 million for FY2024, which is 351.03% down from last year.
- Latest data reveals that Ligand Pharmaceuticals reported Accumulated Depreciation & Amortization of $35.2 million as of Q4 2024, which was down 351.03% from $36.5 million recorded in Q4 2023.
- Ligand Pharmaceuticals' 5-year Accumulated Depreciation & Amortization high stood at $51.5 million for Q4 2022, and its period low was $25.7 million during Q4 2020.
- In the last 5 years, Ligand Pharmaceuticals' Accumulated Depreciation & Amortization had a median value of $36.5 million in 2023 and averaged $40.0 million.
- Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first skyrocketed by 9878.95% in 2021, then tumbled by 2913.22% in 2023.
- Quarter analysis of 5 years shows Ligand Pharmaceuticals' Accumulated Depreciation & Amortization stood at $25.7 million in 2020, then soared by 98.79% to $51.1 million in 2021, then grew by 0.91% to $51.5 million in 2022, then fell by 29.13% to $36.5 million in 2023, then decreased by 3.51% to $35.2 million in 2024.
- Its Accumulated Depreciation & Amortization was $35.2 million in Q4 2024, compared to $36.5 million in Q4 2023 and $51.5 million in Q4 2022.